PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor

PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor

Novel inhibitors of the urokinase-mediated plasminogen (plg) activation system are potentially of great clinical benefit as anticancer treatments. Using phage display, we identified DX-1000 a tissue factor pathway inhibitor-derived Kunitz domain protein which is a specific high-affinity inhibitor o...

Full description

Bibliographic Details
Main Authors: Laetitia Devy, Shafaat A. Rabbani, Mark Stochl, Mary Ruskowski, Ian Mackie, Laurent Naa, Mark Toews, Reinoud van Gool, Jie Chen, Art Ley, Robert C. Ladner, Daniel T. Dransfield, Paula Henderikx
Format: Article
Language:English
Published: Elsevier 2007-11-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Plasmin inhibitor
matrix metal lop roteinases
PEGylation
plasma clearance
antineoplastic agent
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558607800212

Internet

http://www.sciencedirect.com/science/article/pii/S1476558607800212

Similar Items